Trial · NCT07898631
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
NCT07898631, Not applicable, Not yet recruiting, Butler Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide. Trials, record NCT07898631. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898631
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
- NCT number
- NCT07898631
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Butler Hospital
- Conditions
- Suicide, Mental Health Stigma
- Interventions
- RESTEPS
- First posted
- 2026-10-27
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability | At post-intervention (8 weeks post-enrollment) and study follow-up (24 weeks post-enrollment) | The CSQ-8 is a brief, 8-item self-report measure global client satisfaction. Items are measured on a 4-point Likert scale, with higher scores indicating higher levels of satisfaction. The CSQ-8 demonstrates internal consistency, in addition to predictive and convergent validity. A mean CSQ-8 score of ≥ 3 will be used as the satisfaction threshold in the current project. |
| Primary | Suicidal Ideation Questionnaire (SIQ) | At baseline, mid-intervention (4 weeks post enrollment), post-intervention (8 weeks post-enrollment), and study follow-up (24 weeks post-enrollment) | The SIQ is a 15-item self-report measure of suicidal ideation over the past month. Items are rated on a 7- point scale assessing for frequency of thoughts ("almost every day" to "I never had this thought"). Scores range from 0 to 90, with a published clinical cut-off score of 31. It was developed for youth and has established convergent and predictive validity. |
| Secondary | Brief Psychiatric Rating Scale (BPRS) | At baseline, mid-intervention (4 weeks post enrollment), post-intervention (8 weeks post-enrollment), and study follow-up (24 weeks post-enrollment) | The BPRS is an 18-item clinical interview measure of psychopathology, including symptoms of psychosis (e.g., paranoia, hallucinations, delusions), over the past week. Each item is rated on a scale from 1 (not present) to 7 (extremely severe). A higher score on the BPRS suggests higher severity of psychopathology. The BPRS is commonly used in first-episode psychosis intervention studies and has established validity and reliability. The BPRS was designed for adults and the BPRS-C was designed for children/adolescents. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898631
GET https://conductscience.org/api/trials/v1/NCT07898631/registered